# q01 rev 2 - blind solver B (fresh blind-solver, packet solver-2), 2026-10-06

Raw return as received:

**answer:** Flat. At the April 2026 closing, Cencora's fiscal 2026 guidance called for flat adjusted operating income in "Other" (about 0% growth from fiscal 2025's $352M). That was the February 4, 2026 guidance, and the next update came on May 6, 2026.

**confidence:** high

**path:**
1. **Which group held the unit.** From fiscal 2026 the U.S. Consulting Services business sat in "Other", not in either reportable segment.
   - D06 line 121 (Nov 5, 2025): "Beginning in the first quarter of fiscal 2026 ... Other, which is not considered a reportable segment, will consist of businesses for which the Company has begun to explore strategic alternatives and includes MWI Animal Health, Profarma, U.S. Consulting Services and the other components of PharmaLex."
   - D01 line 81 says the same: "other businesses ... have been grouped together in Other. These businesses include MWI Animal Health, Profarma, U.S. Consulting Services, and certain components of PharmaLex." D03 line 86 repeats it.
2. **When it closed.** D05 line 81 (Aug 5, 2026): "U.S. Consulting Services (which was divested in April 2026)". Line 95 says "the April 2026 divestiture of U.S. Consulting Services". Footnotes at lines 269 and 393 agree. No exact day is given anywhere in the packet.
3. **How the "Other" adjusted operating income guidance changed:**
   - D06 line 138 (Nov 5, 2025): "Other(1) | 1% to 4% decline | $352M"
   - D01 line 114 (Feb 4, 2026): "Other(2) | Flat | $352M". The reason given at line 103 is "improved results in Other as certain depreciable assets have been fully impaired as of December 31, 2025".
   - D03 line 123 (May 6, 2026): "Other(2) | High-single digit growth | $352M". Line 112 says this reflects "updated operating income expectations in Other as a result of MWI now being accounted for as 'held for sale'".
   - D05 line 118 (Aug 5, 2026): "Other(2) | ~10% growth | $352M"
4. **Matching the dates.** April 2026 falls between February 4 and May 6, 2026. D03 line 17 says EPS guidance "has been raised from the previous range of $17.45 to $17.75". That is exactly D01's range (line 115), so no guidance update appears between February 4 and May 6. The "Other" change is tied to the May 6 release itself. The guidance in force at the closing was therefore "Flat", which against the $352M fiscal 2025 base means roughly $352M, or about 0% growth.

**minimal_documents:** D01 (the "Flat" figure and the makeup of Other) plus D05 (the April 2026 closing). D03 is strong support: it shows the next change came on May 6, after the closing, with no update in between. No other document replaces D01, since "Flat" appears only there. D03 can't replace D05 because it never mentions the closing. D06 can replace D01 only for the makeup of Other, not for the guidance figure.

**readings:**
- If "at the time of the closing" means the first guidance issued after the closing (D03, May 6, 2026), the answer is "High-single digit growth". But that came after the April closing and reflected the MWI held-for-sale change, so I reject it.
- If "group" means the unit's fiscal 2025 home (D06 line 121 suggests it sat in U.S. Human Health, since the new U.S. segment is "excluding legacy U.S. Consulting Services"), the February guidance for U.S. Healthcare Solutions was 14% to 16% (D01 line 112). That doesn't fit "then included the unit", because Other held it during fiscal 2026. D04 line 83's "specialized consulting services business" in International Healthcare Solutions is a different, fiscal 2025 business, not this unit.
- Other's fiscal 2026 revenue guidance was "1% to 5% growth" (D01 line 110). That is revenue, not operating income, so it doesn't answer the question.

**gaps:**
- The packet gives the closing only as "April 2026", with no exact day. Any April date gives the same answer, because the packet shows no guidance change between February 4 and May 6. Updates made outside earnings releases can't be fully ruled out: D05 line 17 cites a "previous range of $17.70 to $17.90", which shows an update after May 6 that isn't in the packet. Before May 6, though, D03's "previous range" wording rules out an EPS change.
- The footnote "Bolded figures indicate updates to guidance metrics" can't be checked. The docs/ sources are .txt files with no bold formatting and no PDFs, and there are no Dnn.layout.txt files.
- What I read: D01 and D03 in full; D05 lines 1–135 and 255–274; D06 lines 1–190. D02 and D04 were only searched. They contain no fiscal 2026, U.S. Consulting or strategic-alternatives text, apart from D04's fiscal 2025 "specialized consulting services business".

**contaminated:** no. No answer or hints leaked. The packet's question.txt showed up in a directory listing but I didn't open it.

Packet files: `D:\Dev\Docket\tasks\aq-01322\runs\q01-r2-v2-f103b326cdd8df6d9676a1e742d3af3146ddb82878a88e29225208cfa5deaee1\solver-2\text\D01.txt`, `...\text\D03.txt`, `...\text\D05.txt`, `...\text\D06.txt`
